Pharmablock Sciences Nanji (300725.SZ) traded flat 0 % during a 24 hours period ending at 01:30 AM Central Europe on Tuesday 27th. One Pharmablock Sciences Nanji stock can currently be bought for about CNY 43.62 on popular exchanges. Current supply of Pharmablock Sciences Nanji stocks is 233 mn. Pharmablock Sciences Nanji has a current market capitalization of CNY 10.4 bn and approximately CNY 879.6 mn worth of Pharmablock Sciences Nanji was traded on exchanges in the last 24 hours. Since last month end, Pharmablock Sciences Nanji has traded -13.98 % down. Simple moving average of last 200 days is at CNY 42.01. The highest price of past 52 weeks was recorded at CNY 57.55 on 09/30/2026. 52 weeks low was at CNY 30.9 on 06/11/2026.
Here is how related stocks have performed in the past 24 hours:
Fs Com /China-h (3355.HK) traded up 7.14 % and now trades at HKD 37.78. Current market capitalisation for Fs Com /China-h is HKD 14.6 bn.
Wuhan P&s Information Tech (300184.SZ) traded flat 0 % and now trades at CNY 10.36. Current market capitalisation for Wuhan P&s Information Tech is CNY 12.4 bn. Wuhan P&s Information Tech has a current price to earnings ratio of 33.47.
Shenzhen Yinghe (300457.SZ) traded flat 0 % and now trades at CNY 19.2. Shenzhen Yinghe has a market capitalisation of CNY 12.5 bn. Current price/earnings ratio for Shenzhen Yinghe is 19.99.
Suzhou Secote Precision (603283.SS) traded flat 0 % and now trades at CNY 34.43. Suzhou Secote Precision has a market capitalisation of CNY 12.5 bn. Current price/earnings ratio for Suzhou Secote Precision is 22.77.
Central China Land Media (000719.SZ) traded flat 0 % and now trades at CNY 12.4. Current market capitalisation for Central China Land Media is CNY 12.5 bn. Central China Land Media has a current price to earnings ratio of 9.06.
About Pharmablock Sciences Nanji
PharmaBlock Sciences Nanjing Inc. is a health care company operating in the pharmaceutical industry, specializing in providing chemistry products and services for pharmaceutical research and development processes. The company based in Nanjing, China offers scaffolds and building blocks primarily designed based on structural information of marketed drugs, and clinical and preclinical candidates; custom synthesis services; and process research and development services, including synthetic routes scouting, chemistry process development and optimization, impurity identification and profiling, technical package transfer, preclinical manufacturing, and FTE services, as well as manufactures key intermediates and RSMs. The company operates in the People’s Republic of China, North America, Europe, India, Japan, and Australia.
